NCT04791371 Role of Microvascular Insulin Resistance and Cardiorespiratory Fitness Diabetes
| NCT ID | NCT04791371 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Colorado, Denver |
| Condition | Type 2 Diabetes |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2022-06-17 |
| Primary Completion | 2027-01-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 150 participants in total. It began in 2022-06-17 with a primary completion date of 2027-01-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this two-site grant proposal is to determine the role of the decreased insulin-mediated muscle perfusion found in type 2 diabetes in contributing to the development of cardiac and skeletal muscle dysfunction and subsequent functional exercise impairment. In addition, it is also our goal to determine whether exercise training attenuates insulin resistance and restores insulin-mediated perfusion to the heart and to skeletal muscle, leading to improved cardiac function and exercise performance.
Eligibility Criteria
Inclusion Criteria: * Sedentary (defined as less than 1 hour per week of physical activity) * BMI: 25-40 * Men and women with and without type 2 diabetes Exclusion Criteria: * Documented cardiovascular disease * Uncontrolled hypertension: disease systolic blood pressure (SBP) \> 150, diastolic blood pressure (DBP)\> 110 * Obstructive pulmonary disease or asthma * Peripheral neuropathy * Physical impairment that would limit exercise ability * Subjects taking beta blockers, calcium channel blockers, insulin, or Thiazolidinediones (TZD) * Current or past smoking within the last 1 years * Current tobacco use * Anemia * Control HbA1c \> 5.7, T2DM HbA1c \> 9 * Pregnant, nursing or hormonal therapy (other than contraceptives) * Peri or post-menopausal women * Type 1 diabetes * Hepatic or renal disease.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04791371 clinical trial?
This trial is open to participants of all sexes, aged 30 Years or older, up to 55 Years, studying Type 2 Diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04791371 currently recruiting?
Yes, NCT04791371 is actively recruiting participants. Contact the research team at benjamin.juckett@cuanschutz.edu for enrollment information.
Where is the NCT04791371 trial being conducted?
This trial is being conducted at Aurora, United States, Charlottesville, United States.
Who is sponsoring the NCT04791371 clinical trial?
NCT04791371 is sponsored by University of Colorado, Denver. The trial plans to enroll 150 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.